0001567619-22-014379.txt : 20220722 0001567619-22-014379.hdr.sgml : 20220722 20220722184730 ACCESSION NUMBER: 0001567619-22-014379 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220720 FILED AS OF DATE: 20220722 DATE AS OF CHANGE: 20220722 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Clemmer James C CENTRAL INDEX KEY: 0001476700 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50761 FILM NUMBER: 221100774 MAIL ADDRESS: STREET 1: COVIDIEN PLC STREET 2: 15 HAMPSHIRE STREET CITY: MANSFIELD STATE: MA ZIP: 02048 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ANGIODYNAMICS INC CENTRAL INDEX KEY: 0001275187 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 113146460 STATE OF INCORPORATION: DE FISCAL YEAR END: 0531 BUSINESS ADDRESS: STREET 1: 14 PLAZA DRIVE CITY: LATHAM STATE: NY ZIP: 12110 BUSINESS PHONE: 5187981215 MAIL ADDRESS: STREET 1: 14 PLAZA DRIVE CITY: LATHAM STATE: NY ZIP: 12110 4 1 doc1.xml FORM 4 X0306 4 2022-07-20 0 0001275187 ANGIODYNAMICS INC ANGO 0001476700 Clemmer James C 14 PLAZA DIRVE LATHAM NY 12110 1 1 0 0 President and CEO Common Stock 2022-07-20 4 A 0 33094 0 A 440407 D Performance Right 2022-07-20 4 A 0 66187 0 A Common Stock 66187 66187 D Non- Qualified Stock Option (right to buy) 21.53 2022-07-20 4 A 0 77530 0 A 2023-07-20 2032-07-20 Common Stock 77530 77530 D The acquisition of 33,094 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 33,094 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 20, 2023, such that 25% of the restricted stock units will vest on each of July 20, 2023, 2024, 2025 and 2026. Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited. These stock options vest in four equal annual installments beginning on July 20, 2023, such that 25% of the options will vest on each of July 20, 2023, 2024, 2025 and 2026. /s/ Richard C. Rosenzweig, Attorney in Fact 2022-07-22